Continuous glucose monitoring and U.S. market strategy
Name
890374849-MIT.pdf
Description
Full printable version
Size
4.48 MB
Format
Adobe PDF
Checksum (MD5)
2a34569b455d61d5f5768d989608c2e8
Author(s)
Sharma, Shweta Humad
Advisor(s)
Robert Pindyck.
Alternative Title
CGM and U.S. market strategy
Date Issued
2014
Publisher
Massachusetts Institute of Technology
Abstract
There are about 25M (million) diabetics in the US alone, of which only 5-10% of the type 1 diabetics (1M) market has been penetrated with continuous glucose monitoring (CGM) devices. This thesis will provide an overview of the glucose monitoring, then focus on who the key market players for CGM are. Ensuing sections will explore product offerings, understanding what features patients care for and what critical limitations exist in design. It will also tackle why there hasn't been a more widespread adoption of CGM systems considering the technology has been on the market for a decade now. It will dive into a variety of potential market drivers, such as, first mover's advantage, pricing, product attributes and reimbursement coverage. It will emphasize the two US leaders, Medtronic and Dexcom and analyze the companies by comparing their revenue and underlying strategies. Finally the thesis will cover emerging technologies that could pose a market threat to incumbents.
Description
Thesis: M.B.A., Massachusetts Institute of Technology, Sloan School of Management, 2014.
Cataloged from PDF version of thesis.
Includes bibliographical references.
Subjects
Sloan School of Management.
MIT Department
Sloan School of Management
Terms of Use
M.I.T. theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. See provided URL for inquiries about permission.
Persistent DSpace Link
